CN112689630A - 具有双环核部分的新型lxr调节剂 - Google Patents

具有双环核部分的新型lxr调节剂 Download PDF

Info

Publication number
CN112689630A
CN112689630A CN201980056685.2A CN201980056685A CN112689630A CN 112689630 A CN112689630 A CN 112689630A CN 201980056685 A CN201980056685 A CN 201980056685A CN 112689630 A CN112689630 A CN 112689630A
Authority
CN
China
Prior art keywords
alkylene
alkyl
halo
membered
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980056685.2A
Other languages
English (en)
Chinese (zh)
Inventor
C·盖格
O·金泽尔
E·汉布鲁克
M·伯克尔
C·克里莫瑟
U·多伊施勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Levin Ltd
Phoenix Contact Pharmaceutical Co ltd
Original Assignee
Phenex FXR GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenex FXR GmbH filed Critical Phenex FXR GmbH
Publication of CN112689630A publication Critical patent/CN112689630A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
CN201980056685.2A 2018-06-28 2019-06-28 具有双环核部分的新型lxr调节剂 Pending CN112689630A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18180450 2018-06-28
EP18180450.1 2018-06-28
PCT/EP2019/067351 WO2020002611A1 (en) 2018-06-28 2019-06-28 Novel lxr modulators with bicyclic core moiety

Publications (1)

Publication Number Publication Date
CN112689630A true CN112689630A (zh) 2021-04-20

Family

ID=62947921

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980056685.2A Pending CN112689630A (zh) 2018-06-28 2019-06-28 具有双环核部分的新型lxr调节剂

Country Status (27)

Country Link
US (3) US11618747B2 (enExample)
EP (1) EP3814331B9 (enExample)
JP (1) JP7214086B2 (enExample)
KR (1) KR102678581B1 (enExample)
CN (1) CN112689630A (enExample)
AR (1) AR117599A1 (enExample)
AU (1) AU2019293727B2 (enExample)
BR (1) BR112020026405A2 (enExample)
CA (1) CA3104956C (enExample)
CL (1) CL2020003300A1 (enExample)
DK (1) DK3814331T3 (enExample)
EA (1) EA202092821A1 (enExample)
ES (1) ES2956045T3 (enExample)
FI (1) FI3814331T3 (enExample)
HU (1) HUE063538T2 (enExample)
IL (2) IL279722B2 (enExample)
LT (1) LT3814331T (enExample)
MX (1) MX2020014258A (enExample)
PH (1) PH12020552269A1 (enExample)
PL (1) PL3814331T3 (enExample)
PT (1) PT3814331T (enExample)
PY (1) PY1950412A (enExample)
SI (1) SI3814331T1 (enExample)
SM (1) SMT202300334T1 (enExample)
TW (1) TWI748194B (enExample)
UY (1) UY38283A (enExample)
WO (1) WO2020002611A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3796975T (lt) 2018-05-22 2023-12-11 Orsobio, Inc. Sulfonilaminobenzamido dariniai
TWI748194B (zh) 2018-06-28 2021-12-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有雙環核心部分之新穎lxr調節劑
JP7732999B2 (ja) 2020-04-03 2025-09-02 バーテックス ファーマシューティカルズ インコーポレイテッド アルファ１－アンチトリプシンのモジュレーター
IL296920A (en) * 2020-04-03 2022-12-01 Vertex Pharma Indole derivatives as alpha-1-antitrypsin modulators for the treatment of alpha-1-antitrypsin deficiency (aatd)
EP4611746A1 (en) * 2022-11-03 2025-09-10 OrsoBio, Inc. Lxr modulators with bicyclic core moiety for treating dyslipidemias

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1476432A (zh) * 2000-11-28 2004-02-18 - 吲哚和二氢吲哚衍生物
TW200602320A (en) * 2004-05-20 2006-01-16 Sankyo Co Indol compounds
TW200637816A (en) * 2005-04-07 2006-11-01 Sankyo Co Substituted indole compound
CN1863528A (zh) * 2003-10-10 2006-11-15 P.安杰莱蒂分子生物学研究所 作为抗病毒剂的吲哚和吖吲哚
CN1950365A (zh) * 2004-05-03 2007-04-18 霍夫曼-拉罗奇有限公司 作为肝脏－x－受体调节剂的吲哚基衍生物
TW200745031A (en) * 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
CN101184731A (zh) * 2005-05-30 2008-05-21 实验室富尼耶公司 新的吲哚啉化合物
CN101213194A (zh) * 2004-08-03 2008-07-02 惠氏公司 可用于治疗心血管疾病的吲唑化合物
US20100184598A1 (en) * 2007-04-26 2010-07-22 Syngenta Participations Ag 4-aza indole derivatives and their use as fungicides
CN105209039A (zh) * 2013-03-15 2015-12-30 百时美施贵宝公司 Lxr调节剂
CN108137497A (zh) * 2015-06-23 2018-06-08 法国施维雅药厂 新的二环衍生物、其制备方法以及含有它们的药物组合物
WO2018188795A1 (en) * 2017-04-10 2018-10-18 Phenex-Fxr Gmbh Liver x receptors (lxr) modulators
WO2019016269A1 (en) * 2017-07-18 2019-01-24 Phenex-Fxr Gmbh MODULATORS OF LXR BASED ON AMINE OR (THIO) AMIDE

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290798A (en) 1991-09-30 1994-03-01 Merck Frosst Canada, Inc. (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5308850A (en) 1991-09-30 1994-05-03 Merck Frosst Canada, Inc. (Bicyclic-hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
JPH06145150A (ja) 1992-11-09 1994-05-24 Kyowa Hakko Kogyo Co Ltd イミダゾール誘導体
KR20000057137A (ko) 1996-11-19 2000-09-15 스티븐 엠. 오드레 아릴 및 헤테로아릴로 치환된 융합 피롤 항염증제
WO1998022452A1 (en) 1996-11-19 1998-05-28 Kyowa Hakko Kogyo Co., Ltd. Benzofuran derivatives
US6172084B1 (en) 1997-06-19 2001-01-09 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
ATE499365T1 (de) 1997-10-24 2011-03-15 Nissan Chemical Ind Ltd Sulfamoyl-verbindungen und bakterizide für landwirtschaft oder gartenbau
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
AU1215701A (en) 1999-10-22 2001-05-08 Merck & Co., Inc. Pharmaceuticals for treating obesity
AU2001280187A1 (en) 2000-08-28 2002-03-13 Toray Industries, Inc. Cyclic amine derivatives
KR100823908B1 (ko) 2000-10-20 2008-04-21 바이오비트럼 에이비(피유비엘) 2-, 3-, 4-, 또는 5-치환-ｎ1-(벤젠술포닐)인돌 및 이의치료 용도
JP4184077B2 (ja) 2000-11-02 2008-11-19 ワイス ５−ヒドロキシトリプトアミン−６リガンドとしての１−アリールまたは１−アルキルスルホニル−ヘテロシクリルベンザゾール
WO2002051837A2 (en) 2000-12-22 2002-07-04 Wyeth Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
US7560586B2 (en) 2002-03-27 2009-07-14 Smithkline Beecham Corporation Acid and ester compounds and methods of using the same
IL165863A0 (en) 2002-06-24 2006-01-15 Schering Corp Indole derivatives useful as histamine H3 antagonists
ES2228267B1 (es) 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
WO2005077122A2 (en) 2004-02-11 2005-08-25 Irm Llc Compounds and compositions as lxr modulators
WO2005085188A2 (en) 2004-03-02 2005-09-15 Compass Pharmaceuticals Llc Compounds and methods for anti-tumor therapy
WO2007134169A2 (en) 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US20080319044A1 (en) 2004-11-01 2008-12-25 Nuada, Llc Compounds and Methods of Use Thereof
EP1965862A2 (en) 2005-12-21 2008-09-10 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
EP2041131B1 (en) 2006-07-06 2011-09-28 Abbott Healthcare Products B.V. Azaindole derivatives with a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition
TW200825054A (en) 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
US8507469B2 (en) 2007-03-23 2013-08-13 Abbott Gmbh & Co. Kg Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
AU2008234017B2 (en) 2007-03-30 2011-09-22 F. Hoffmann-La Roche Ag Imidazolidinone derivatives
WO2009032116A1 (en) 2007-08-29 2009-03-12 Schering Corporation 2, 3-substituted indole derivatives for treating viral infections
ATE541845T1 (de) 2007-08-29 2012-02-15 Schering Corp 2,3-substituierte azaindolderivate zur behandlung von virusinfektionen
US8377928B2 (en) 2007-11-16 2013-02-19 Merck Sharp & Dohme Corp. 3-aminosulfonyl substituted indole derivatives and methods of use thereof
MX2010005356A (es) 2007-11-16 2010-05-27 Schering Corp Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
EP2210891A1 (en) 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
EP2245936A1 (en) 2009-04-27 2010-11-03 Bayer CropScience AG Use of 4-aza indole derivatives for the reduction of mycotoxin contamination
KR20120049214A (ko) 2009-06-08 2012-05-16 악셀레론 파마 인코포레이티드 발열성 지방세포를 증가시키는 방법
WO2013012649A1 (en) 2011-07-15 2013-01-24 Glaxosmithkline Llc Azaindole compounds and methods for treating hiv
WO2013028999A1 (en) 2011-08-24 2013-02-28 The Trustees Of Columbia University In The City Of New York Small molecule inducers of gdnf as potential new therapeutics for neuropsychiatric disorders
RU2672468C1 (ru) 2011-12-22 2018-11-15 Конекшис Лайф Сайенсиз Пвт. Лтд. Производные аза-адамантанов и их применение
KR20130142801A (ko) 2012-06-20 2013-12-30 안국약품 주식회사 １１β－ＨＳＤ１ 효소의 억제활성을 갖는 신규한 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
US9376420B2 (en) * 2012-10-25 2016-06-28 Yuhan Corporation 4,5-dihydro-1H-pyrazole derivative or salts thereof, and pharmaceutical composition comprising same
WO2014085453A2 (en) 2012-11-29 2014-06-05 The Scripps Research Institute Small molecule lxr inverse agonists
EP2990403A1 (en) 2014-08-29 2016-03-02 Novartis Tiergesundheit AG Anthranilamides, sulfonamides and nitro analogues derived therefrom as anthelmintics
CA2968299A1 (en) 2014-11-18 2016-05-26 Rutgers, The State University Of New Jersey Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer
AR103232A1 (es) 2014-12-22 2017-04-26 Bristol Myers Squibb Co ANTAGONISTAS DE TGFbR
US10227315B2 (en) 2016-05-18 2019-03-12 Rutgers, The State University Of New Jersey Mitochondrial uncouplers for treatment of metabolic diseases and cancer
LT3796975T (lt) 2018-05-22 2023-12-11 Orsobio, Inc. Sulfonilaminobenzamido dariniai
TWI748194B (zh) 2018-06-28 2021-12-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有雙環核心部分之新穎lxr調節劑
US20200397807A1 (en) 2019-06-18 2020-12-24 MitoPower, LLC Nicotinyl riboside compounds and their uses
EP4611746A1 (en) 2022-11-03 2025-09-10 OrsoBio, Inc. Lxr modulators with bicyclic core moiety for treating dyslipidemias

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1476432A (zh) * 2000-11-28 2004-02-18 - 吲哚和二氢吲哚衍生物
CN1863528A (zh) * 2003-10-10 2006-11-15 P.安杰莱蒂分子生物学研究所 作为抗病毒剂的吲哚和吖吲哚
US20070072911A1 (en) * 2003-10-10 2007-03-29 Salvatore Avolio Indoles and azaindoles as antiviral agents
CN1950365A (zh) * 2004-05-03 2007-04-18 霍夫曼-拉罗奇有限公司 作为肝脏－x－受体调节剂的吲哚基衍生物
TW200602320A (en) * 2004-05-20 2006-01-16 Sankyo Co Indol compounds
CN101213194A (zh) * 2004-08-03 2008-07-02 惠氏公司 可用于治疗心血管疾病的吲唑化合物
TW200637816A (en) * 2005-04-07 2006-11-01 Sankyo Co Substituted indole compound
CN101184731A (zh) * 2005-05-30 2008-05-21 实验室富尼耶公司 新的吲哚啉化合物
TW200745031A (en) * 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
US20100184598A1 (en) * 2007-04-26 2010-07-22 Syngenta Participations Ag 4-aza indole derivatives and their use as fungicides
CN105209039A (zh) * 2013-03-15 2015-12-30 百时美施贵宝公司 Lxr调节剂
CN108137497A (zh) * 2015-06-23 2018-06-08 法国施维雅药厂 新的二环衍生物、其制备方法以及含有它们的药物组合物
WO2018188795A1 (en) * 2017-04-10 2018-10-18 Phenex-Fxr Gmbh Liver x receptors (lxr) modulators
WO2019016269A1 (en) * 2017-07-18 2019-01-24 Phenex-Fxr Gmbh MODULATORS OF LXR BASED ON AMINE OR (THIO) AMIDE
CN110914248A (zh) * 2017-07-18 2020-03-24 菲尼克斯-Fxr股份有限公司 含有胺或(硫代)酰胺的lxr调节剂

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
QU, CHUANHUA等: "Cascade photoredox/gold catalysis: access to multisubstituted indoles via aminoarylation of alkynes" *
WANG, ZE-SHU等: "Dual gold/photoredox-catalyzed bis-arylative cyclization of chiral homopropargyl sulfonamides with diazonium salts: rapid access to enantioenriched 2,3-dihydropyrroles" *
YOUN, SO WON等: "Unusual 1,2-aryl migration and depalladation of alkylpalladium intermediates containing a syn-β-hydrogen atom" *

Also Published As

Publication number Publication date
PY1950412A (es) 2021-10-27
US11618747B2 (en) 2023-04-04
LT3814331T (lt) 2023-08-10
FI3814331T3 (fi) 2023-08-23
IL310623A (en) 2024-04-01
PH12020552269A1 (en) 2021-07-19
CL2020003300A1 (es) 2021-07-02
TWI748194B (zh) 2021-12-01
PT3814331T (pt) 2023-07-04
AU2019293727B2 (en) 2022-06-30
CA3104956C (en) 2023-11-28
IL279722B2 (en) 2024-07-01
EP3814331A1 (en) 2021-05-05
ES2956045T3 (es) 2023-12-12
US12291523B2 (en) 2025-05-06
EP3814331B9 (en) 2023-08-09
IL279722B1 (en) 2024-03-01
CA3104956A1 (en) 2020-01-02
EP3814331B1 (en) 2023-06-14
AR117599A1 (es) 2021-08-18
KR20210025636A (ko) 2021-03-09
HUE063538T2 (hu) 2024-01-28
TW202019907A (zh) 2020-06-01
JP2021528451A (ja) 2021-10-21
NZ772148A (en) 2024-05-31
WO2020002611A1 (en) 2020-01-02
JP7214086B2 (ja) 2023-01-30
EA202092821A1 (ru) 2021-05-21
PL3814331T3 (pl) 2023-11-13
US20230357214A1 (en) 2023-11-09
US20240317726A1 (en) 2024-09-26
IL279722A (en) 2021-03-01
SMT202300334T1 (it) 2023-11-13
SI3814331T1 (sl) 2023-08-31
UY38283A (es) 2020-01-31
DK3814331T3 (da) 2023-08-14
US11970484B2 (en) 2024-04-30
BR112020026405A2 (pt) 2021-04-06
MX2020014258A (es) 2021-05-27
KR102678581B1 (ko) 2024-06-25
US20210147398A1 (en) 2021-05-20
AU2019293727A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
KR102678581B1 (ko) 바이사이클릭 코어 모이어티를 갖는 신규한 lxr 조절제
KR102732835B1 (ko) 파르네소이드 x 수용체 조정제로서의 가교된 비시클릭 화합물
TW201835070A (zh) 芳香烴受體(AhR)調節劑化合物
WO2019101086A1 (zh) 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
CN114409656B (zh) Pim激酶抑制剂
CN110546144A (zh) 肝x受体(lxr)调节剂
CN110914248A (zh) 含有胺或(硫代)酰胺的lxr调节剂
JP2018138609A (ja) ナフチリジンジオン誘導体
WO2023165334A1 (zh) 酮酰胺类衍生物及其制药用途
HK40052052B (en) Novel lxr modulators with bicyclic core moiety
HK40052052A (en) Novel lxr modulators with bicyclic core moiety
WO2020148325A1 (en) Neutral lxr modulators
EA045482B1 (ru) Новые модуляторы lxr с бициклическим центральным фрагментом

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20220530

Address after: California, USA

Applicant after: Levin Ltd.

Address before: Heidelberg, Germany

Applicant before: Phoenix Contact Pharmaceutical Co.,Ltd.

Effective date of registration: 20220530

Address after: Heidelberg, Germany

Applicant after: Phoenix Contact Pharmaceutical Co.,Ltd.

Address before: Heidelberg, Germany

Applicant before: PHENEX-FXR GmbH

TA01 Transfer of patent application right
CB02 Change of applicant information

Address after: California, USA

Applicant after: Ossur Biotech

Address before: California, USA

Applicant before: Levin Ltd.

CB02 Change of applicant information